Expanding the therapeutic window of bacteria for cancer therapy

A hypoxia-lactate “AND gate” engineered tumor-restricted bacterium expands the maximum tolerated dose by up to 1,000-fold in mice, while preserving antitumour activity.

• Why it matters: Self-amplifying bacterial therapies can cause systemic toxicity and off-target growth, limiting safe dosing and narrowing the therapeutic window.
• What they did: The authors engineered a “tumorobe” by combining lipopolysaccharide modifications to reduce immunogenicity, tumour-only growth control, and lipoprotein deletion to boost extracellular payload release.
• The result: In multiple murine models, including colorectal cancer and glioblastoma, it produced robust antitumour effects and durable complete responses in up to 75% of colorectal tumours when delivering a cytokine payload.

AI summary of the abstract · may contain errors · not medical advice · read the paper.